Herman Miller, Inc. (NASDAQ:MLHR) reports Q4 earnings

Herman Miller, Inc. (NASDAQ:MLHR) reported fourth-quarter earnings and sales that beat expectations, and raised its dividend by 6% to 21 cents per share payable in October 2019. Net income for the quarter totaled $46.2 million, or 78 cents per share, up from $31.8 million, or 53 cents per share, last year. Adjusted EPS was 88 cents, ahead of the 78-cent FactSet consensus. Sales reached a record $671.0 million, according to Chief Executive Andi Owen, up from $618.0 million and beating the FactSet consensus of $657.0 million.

Herman Miller, Inc. (NASDAQ:MLHR), a Consumer Goods sector firm, traded 3.12 Million shares in last trading session with closing price of $44.09 per share. Company gross margin stands at 36.20% whereas its return on investment (ROI) is 13.10%. Stock value has moved between $28.63 – 40.82 in last one year. Analyst’s mean target price for Herman Miller, Inc. (NASDAQ:MLHR) is $41.00 while analysts mean recommendation is 2.20. MLHR EPS growth this year is -5.80%. 

On last trading day, Spero Therapeutics, Inc. (NASDAQ:SPRO) shares closed at $11.11 per share. SPRO market capitalization is 194.42. Analyst’s mean target price for Spero Therapeutics, Inc. (NASDAQ:SPRO) is $23.00 whereas analysts mean recommendation is 2.00. Its weekly performance is -18.19% while year to date (YTD) performance is 80.65%. 

In last session Huron Consulting Group Inc. (NASDAQ:HURN) traded 77569 shares and was closed at $49.86. Analyst’s mean target price for HURN is $58.33. Company is -12.53% away from its 52 week high and is moving 23.42% ahead of its 52 week low. HURN Gross Margin is 30.90% and its return on assets is 1.90%. Huron Consulting Group Inc. (NASDAQ:HURN) quarterly performance is 3.47% while its price to sale ratio is 1.28. 

Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a Healthcare sector firm, traded 14006 shares on last trading day with closing price of $10.70 per share. Company return on investment (ROI) is -91.70%. Stock value has moved between $6.9 – 13.9 in last one year. Analyst’s mean target price for Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) is $28.25. ARDS EPS growth this year is 16.80%. 

READ  General Motors Company (NYSE:GM) would invest $20 million to upgrade equipment at automaker's Arlington Assembly plant

Leave a Reply

Read previous post:
Rocking Stock: Amgen Inc. (NASDAQ:AMGN), Vistra Energy Corp. (NYSE:VST), JPMorgan Chase & Co. (NYSE:JPM), Halliburton Company (NYSE:HAL)

Amgen Inc. (NASDAQ:AMGN), and UCB (Euronext Brussels: UCB) announced that the companies have been informed the Committee for Medicinal Products...